Robotics company Wandercraft has raised $75m in a Series D funding round to introduce the self-balancing personal exoskeleton, Eve, to market by 2026.
This investment will fuel the company’s growth and the expansion of its flagship rehabilitation system, Atalante X, which received FDA clearance.
After receiving second clearance, Atalante X鈥檚 use was expanded to US hospitals and clinics.
It will also support the development and deployment of Calvin-40, Wandercraft’s humanoid robot.
The Series D round saw significant contributions from Renault Group, PSIM fund, Quadrant Management, and Teampact Ventures, among others.
Since its last funding round, Wandercraft has experienced substantial growth, with a tenfold revenue increase propelled by the commercial expansion in the US.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe Series D funding follows a strategic partnership and minority stake acquisition by Renault Group, which will leverage its industrial know-how to scale up production of exoskeletons and robots of Wandercraft.
This industrial-grade robot, capable of performing physically demanding tasks, is said to have been developed in just 40 days using Wandercraft’s quick development process and integrated with NVIDIA’s Isaac technologies.
Wandercraft co-founder and CEO Matthieu Masselin said: “The momentum we鈥檝e achieved over the past few years is extraordinary.
鈥淲e鈥檝e expanded globally, launched pivotal clinical trials, readied the commercialisation of Eve, our personal exoskeleton, and entered a landmark partnership with Renault Group.鈥�
Wandercraft’s Atalante X is currently leveraged to assist individuals with disabilities in over 100 rehabilitation centres across four continents.
The introduction of Eve aims to aid the users of wheelchairs by enabling standing and walking in daily life.
